Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Homo sapiens | muscleblind-like splicing regulator 1 | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | neutral sphingomyelinase | 0.012 | 0.6433 | 1 |
Echinococcus multilocularis | neutral sphingomyelinase | 0.012 | 0.6433 | 0.6433 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0026 | 0.0949 | 0.5 |
Echinococcus granulosus | muscleblind protein | 0.018 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.2936 | 0.2551 |
Toxoplasma gondii | exonuclease III APE | 0.0026 | 0.0949 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0026 | 0.0949 | 1 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0026 | 0.0949 | 0.5 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.0518 | 0.0518 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1817 | 0.137 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0026 | 0.0949 | 0.5 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.7871 | 0.7755 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0026 | 0.0949 | 0.5 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0026 | 0.0949 | 0.0949 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.7871 | 0.7755 |
Echinococcus multilocularis | muscleblind protein 1 | 0.018 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1817 | 0.2824 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0518 | 0.0518 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Echinococcus multilocularis | muscleblind protein | 0.018 | 1 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0026 | 0.0949 | 1 |
Echinococcus multilocularis | expressed conserved protein | 0.0111 | 0.5947 | 0.5947 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0026 | 0.0949 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.018 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Onchocerca volvulus | Putative neutral sphingomyelinase | 0.012 | 0.6433 | 0.5 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0026 | 0.0949 | 0.5 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0518 | 0.0518 |
Loa Loa (eye worm) | hypothetical protein | 0.012 | 0.6433 | 0.6238 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0026 | 0.0949 | 0.0455 |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0026 | 0.0949 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2936 | 0.2551 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0026 | 0.0949 | 0.0949 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0026 | 0.0949 | 0.0455 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0026 | 0.0949 | 0.5 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.7871 | 0.7755 |
Schistosoma mansoni | ap endonuclease | 0.0026 | 0.0949 | 0.1475 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0518 | 0.0518 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.2936 | 0.2551 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0026 | 0.0949 | 1 |
Schistosoma mansoni | ap endonuclease | 0.0026 | 0.0949 | 0.1475 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0026 | 0.0949 | 1 |
Brugia malayi | Endonuclease/Exonuclease/phosphatase family protein | 0.012 | 0.6433 | 0.6238 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1817 | 0.137 |
Echinococcus granulosus | hypothetical protein | 0.0111 | 0.5947 | 0.5947 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.0518 | 0.0518 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0026 | 0.0949 | 1 |
Mycobacterium leprae | PROBABLE BACTERIOFERRITIN BFRA | 0.001 | 0 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0026 | 0.0949 | 1 |
Echinococcus granulosus | neutral sphingomyelinase | 0.012 | 0.6433 | 0.6433 |
Echinococcus granulosus | expressed conserved protein | 0.0111 | 0.5947 | 0.5947 |
Echinococcus multilocularis | conserved hypothetical protein | 0.0111 | 0.5947 | 0.5947 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0518 | 0.0805 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0518 | 0.0518 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.2936 | 0.2551 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.7079 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 8.2753 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 14.7157 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (binding) | = 17.7828 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (binding) | 19.9526 uM | PubChem BioAssay. qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5962 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | = 25.1189 um | PUBCHEM_BIOASSAY: qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent). (Class of assay: confirmatory) [Related pubchem assays: 2158 (Confirmation qHTS Assay for Inhibitors of Cruzain), 2249 (Probe Development Summary of Promiscuous Inhibitors (Artifacts) of Cruzain), 2161 (qHTS Assay for Inhibitors of Papain: Counterscreen for Cruzain Assay), 1478 (qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent))] | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 35.4813 um | PUBCHEM_BIOASSAY: qHTS Assay for Enhancers of SMN2 Splice Variant Expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.